- Policy
- Will Boryung succeed in tackling Sprycel’s patent
- by Lee, Tak-Sun Dec 30, 2021 05:51am
- Whether a generic for the second-generation chronic myeloid leukemia treatment ‘Sprycel (dasatinib, BMS)’ will be introduced following generics for the first-generation ‘Gleevec (imatinib mesylate, Novartis)' is gaining attention. If introduced, Sprycel’s generic is expected to greatly improve patient accessibility. According to th
- Policy
- The MFDS plans to approve Daewoong's Fexuprazan
- by Lee, Tak-Sun Dec 30, 2021 05:51am
- Fexuprazan, a new drug for GERD that Daewoong Pharmaceutical has researched and developed for 14 years, is expected to obtain domestic approval soon. When Fexuprazan is released, Daewoong is expected to fill the gap in the PPI-based treatment Nexium. According to the industry on the 28th, the MFDS completed the safety and effectiveness exa
- Policy
- Paxlovid is a new weapon added to our fight against COVID-19
- by Lee, Jeong-Hwan Dec 29, 2021 05:58am
- “An oral-type treatment will be prescribed to patients with severe or critical COVID-19 that are unsuitable to be treated with an injection-type (antiviral). In other words, we have secured another option in our armory to use against COVID-19.” Ministry of Food and Drug Safety Minister Gang-lip Kim This is what Minister Gang-lip
- Policy
- Gov-National Assembly introduce oral treatment for COVID-19
- by Lee, Jeong-Hwan Dec 29, 2021 05:57am
- As COVID-19 spreads to the Omicron mutation following the delta mutation, and the number of deaths and new confirmed patients increases, the attention of the National Assembly and the government is focusing on treatments.The National Assembly's Health and Welfare Committee is urging the U.S. FDA to preemptively secure domestic antibody treat
- Policy
- Entry of FDA-approved new Chinese blood cancer drug imminent
- by Lee, Tak-Sun Dec 28, 2021 05:51am
- A new blood cancer treatment that was developed by a Chinese pharmaceutical company and approved by the US FDA will be soon introduced to Korea. The drug awaiting entry is BeiGene Korea’s ‘Brukinsa.’ If approved, Brukinsa will be the second new drug approved by a Chinese pharmaceutical company following Antengene’s ‘Xpovio tab 20mg.
- Policy
- MFDS approves emergency use of Pfizer’s oral COVID-19 drug
- by Lee, Tak-Sun Dec 28, 2021 05:50am
- Pfizer’s oral COVID-19 treatment ‘Paxlovid’ received emergency use authorization in Korea as well. Authorities plan to use the drug to treat adults and pediatric patients over the age of 12 with mild-to-moderate COVID-19 at high risk of progressing to severe disease. Pharmacies will be supplying the pills for patients treated from thei
- Policy
- AstraZeneca Xigduo’s latecomers consecutively approved
- by Lee, Tak-Sun Dec 27, 2021 05:57am
- Latecomers of AstraZeneca’s SGLR-2 antidiabetic combination therapy ‘Xigduo XR (dapagliflozin propanediol/metformin) are receiving approval. Due to the patent period set for the original’s substance patent, the latecomers will only be available for sale from April 2023, however, due to its commerciality and patent issues, companies ar
- Policy
- Roche applies for approval of its new drug faricimab
- by Lee, Tak-Sun Dec 27, 2021 05:56am
- The global pharmaceutical company Roche has applied for the approval of its newly developed treatment for macular degeneration, ‘faricimab.’ The company had submitted an application for faricimab in the US, Europe, and Japan. If approved, the drug will be competing with Bayer’s ‘Eylea (aflibercept)’ and Novartis’ ‘Beovu (brolucizum
- Policy
- The suspension of execution for Legalon has been extended
- by Kim, Jung-Ju Dec 27, 2021 05:56am
- It is an extension of the grace period for deleting insurance drug benefits due to prolonged lawsuits. Abbott's Cholib, which item license has been revoked by the licensing authority, is automatically removed from the list according to the company's decision to withdraw from the market. The MOHW announced the court's decision to extend the su
- Policy
- What are the variables for the release of Forxiga+ Januvia?
- by Lee, Tak-Sun Dec 24, 2021 05:49am
- Daewon Pharmaceutical and Dongkoo Bio's combination of Dapagliflozin (Forxiga) and Sitaglipin (Januvia) is approved. Since both ingredients are widely used in the diabetes treatment market, attention is being paid to whether there will be a change in the market due to the emergence of complex drugs. However, there are still steps to over
